Development of Ivermectin for Alcohol Use Disorders
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
Current pharmacotherapies for alcohol use disorders (AUDs) have limited efficacy. Thus, the
development of effective treatments for AUDs represents an important public health objective.
Repositioning, i.e. using existing approved drugs for other indications, represents a fast
and economically feasible approach for drug development. Ivermectin (IVM) is an FDA-approved
antiparasitic medication that can significantly reduce alcohol intake in mice, suggesting
that it may be useful in the treatment of AUDs in humans. The goal of this project is to
provide key clinical evidence that IVM can be repositioned as a novel therapeutic agent to
treat AUDs.